First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation

Zidek, Walter; Schrader, Joachim; L�ders, Stephan; Matthaei, Stephan; Hasslacher, Christoph; Hoyer, Joachim; Bramlage, Peter; Sturm, Claus-Dieter; Paar, W. Dieter
January 2008
Cardiovascular Diabetology;2008, Vol. 7, p1
Academic Journal
Background: Recent clinical trials reported conflicting results on the reduction of new-onset diabetes using RAS blocking agents. Therefore the role of these agents in preventing diabetes is still not well defined. Ramipril is an ACE inhibitor (ACEi), that has been shown to reduce cardiovascular events in high risk patients and post-hoc analyses of the HOPE trial have provided evidence for its beneficial action in the prevention of diabetes. Methods: The ADaPT investigation ("ACE inhibitor-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes") is a 4-year open, prospective, parallel group phase IV study. It compares an antihypertensive treatment regimen based on ramipril versus a treatment based on diuretics or betablockers. The primary evaluation criterion is the first manifestation of type 2 diabetes. The study is conducted in primary care to allow the broadest possible application of its results. The present article provides an outline of the rationale, the design and baseline characteristics of AdaPT and compares these to previous studies including ASCOT-BLPA, VALUE and DREAM. Results: Until March 2006 a total of 2,015 patients in 150 general practices (general physicians and internists) throughout Germany were enrolled. The average age of patients enrolled was 67.1 � 10.3 years, with 47% being male and a BMI of 29.9 � 5.0 kg/m�. Dyslipidemia was present in 56.5%. 37.8% reported a family history of diabetes, 57.8% were previously diagnosed with hypertension (usually long standing). The HbA1c value at baseline was 5.6 %. Compared to the DREAM study patients were older, had more frequently hypertension and patients with cardiovascular disease were not excluded. Conclusion: Comparing the ADaPT design and baseline data to previous randomized controlled trial it can be acknowledged that AdaPT included patients with a high risk for diabetes development. Results are expected to be available in 2010. Data will be highly valuable for clinical practice due to the observational study design.


Related Articles

  • Once-Weekly BYDUREON(tm) Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir(r) in Type 2 Diabetes.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Amylin Pharmaceuticals Inc. and Alkermes PLC has released the results from its clinical trials of BYDUREON and Levemir for the treatment of type 2 diabetes. A comparative study revealed that BYDUREON is a once weekly treatment which is more efficient in controlling...

  • BYDUREON(tm) Was Associated with Significant and Sustained Glycemic Control at Four Years.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Amylin Pharmaceuticals Inc. and Alkermes PLC has released the results from its clinical trial of BYDUREON for the treatment of type 2 diabetes. It mentions that the efficacy of once-weekly treatment BYDUREON and twice-daily BYETTA was compared which revealed that...

  • BYETTA(r) Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl(r) in Patients with Type 2 Diabetes.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that Amylin Pharmaceuticals Inc. has released the results from its comparative clinical trial of BYETTA and Amaryl for the treatment of type 2 diabetes. It mentions that BYETTA resulted in glycemic durability, weight loss and reduced risk of hypoglycemia. It further informs...

  • A Novel Antihypertensive Effect of Exenatide, a GLP-1 Agonist. Dandona, Paresh; Chaudhuri, Ajay; Dhindsa, Sandip // American Journal of Hypertension;Mar2010, Vol. 23 Issue 3, p228 

    In this article the author comments on the anti-hypertensive efficacy of the glucan-like peptide-1 (GLP-1) exenatide for the treatment of hypertension and prevention from hyperglycemia. The author is particular on the consistent reduction of systolic blood pressure among 2,171 patients with type...

  • Patiromer effective for drug-associated hyperkalaemia.  // Reactions Weekly;Aug2015, Vol. 1562 Issue 1, p10 

    The article discusses research published in the July 14, 2015 issue of "The Journal of the American Medical Association" that investigated the efficacy of patirometer in patients with type 2 diabetes mellitus receiving renin-angiotensin-aldosterone system (RAAS) inhibitors.

  • Finding ACCORD in the Management of Type 2 Diabetes?  // Critical Care Alert;May2010 Pharmacology, p1 

    The article offers information on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial which is intended to complement the management of type 2 diabetes.

  • Trend of clinical drug trials in type 2 diabetes mellitus over last decade. Parikh, Rakesh; Pandia, Kirti; Goyal, Mahesh; Sharma, Meenakshi; Dolima, M. S. // Perspectives in Clinical Research;2011, Vol. 2 Issue 2, p64 

    Background: Type 2 diabetes mellitus (Type 2 DM) has been recognized as the recent pandemic; India and China competing each other for the title--"Diabetes Capital of the World." A number of new drugs have been recently available and has lead to a boom in the clinical drug trial industry. We...

  • Combination Therapy Clinical Trials.  // Pharmacy Today;Sep2011 Supplement, p4 

    The article focuses on the clinical trials that evaluate the efficacy and safety of dipeptidyl-peptidase-4 (DDP-4) inhibitor called Tradjenta as an add-on therapy to metformin and pioglitazone in patients with type 2 diabetes with inadequate glycemic control.

  • Comparative efficacy of humalog mix 75/25 with human Insulin. Wal, Pranay; Wal, Ankita; Srivastava, Shivangi; Srivastava, Abhinav; Pandey, Umeshwar; Jain, Tarun; Rai, Awani K. // Journal of Pharmaceutical Sciences & Research;2010, Vol. 2 Issue 5, p302 

    The study is designed to compare the postprandial glucodynamic profile of humalog mix 75/25, a new premixed insulin analogue containing 75% neutral protamine lispro and 25% insulin lispro with that of human insulin 70/30 in patients with type 2 diabetes mellitus. Insulin lispro mix 75/25 is the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics